Medidata, Circuit Clinical partner in decentralized clinical trial push

By Nick Taylor

- Last updated on GMT

(Tetiana Lazunova/iStock via Getty Images Plus)
(Tetiana Lazunova/iStock via Getty Images Plus)

Related tags Medidata Circuit Clinical Decentralized trials Virtual clinical trials COVID-19 Data management

Integrated research organization Circuit Clinical will standardize its decentralized operations with Medidata’s RAVE and myMedidata technological offerings.

Medidata has partnered with integrated research organization Circuit Clinical to step up its decentralized clinical trial (DCT) offering.

Circuit Clinical, like other integrated research organizations, is focused on enabling patients to choose clinical research as a care option. Now, Circuit Clinical is investing to expand its DCT network to meet the rise in demand for decentralized trials.

The COVID-19 pandemic has propelled interest in and adoption of DCTs. As the landscape of clinical trials has evolved, scalable, flexible, and intuitive solutions are necessary. The next era of clinical trials is underway, and the fuel for success will be improvements in patient, site, and sponsor experiences​,” said Kelly McKee, vice president of patient registries and recruitment at Medidata.

Through the alliance, Circuit Clinical will standardize its DCT sites on Medidata’s RAVE and myMedidata technologies. Today, Circuit Clinical has a network of 90 doctors across more than 30 sites and is working to grow its operation.

Investors are supporting the expansion. With Medidata contributing to a $27m financing round, Circuit Clinical plans to expand its network to cover 500 physician investigators and 15m patients.

McKee foresees the use of Medidata technologies at Circuit Clinical sites resulting in faster study starts and improved patient recruitment while enabling optimization to any level of study decentralization.

Kelly McKee, vice president of patient registries and recruitment, Medidata

It is critical for patients, sponsors, and sites to have a single platform for all their clinical trial needs​,” said McKee. “Implementing the right level of decentralization using an end-to-end, unified, and secure platform allows sponsors to improve chances of trial success, increase protocol adherence and safety monitoring, and bring value to patients, sites, and sponsors​.”   

Circuit Clinical will invite its participating healthcare systems to join myMedidata Clinical Trial Patient Registries. In doing so, the partners aim to raise awareness of, and access to, clinical trial opportunities.

Study subjects will have the opportunity to rate and review their experiences of participating in clinical trials using Circuit Clinical’s TrialJourney system. The partners are aiming to improve the experiences of patients and, in doing so, make it easier to retain patients. Today, Circuit Clinical claims a 93% retention rate across all projects.

Circuit Clinical’s current offering covers cardiovascular disease, diabetes, women’s health, kidney disease, digestive diseases, rheumatoid arthritis, cancer, COVID-19, and other therapeutic areas.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us